Appendix 4C

Quarter Ended 30 September 2024

Chimeric Therapeutics Limited

ACN 638 835 828

ASX: CHM

ASX ANNOUNCEMENT **30 OCTOBER 2024**

QUARTERLY ACTIVITIES REPORT FOR THE PERIOD ENDING 30 SEPTEMBER 2024

Sydney, Australia, 30 October 2024: Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 30 September 2024.

- First patient enrolled and dosed in CHM CDH17 Phase 1/2 trial at Sarah Cannon Research Institute in Nashville
- Trial will inform dose selection, followed by Phase 2 expansion into specific cancer cohorts
- Collaboration with Achieve Clinics to expand patient access to CHM CDH17 through the use of Achieve's PRO-Aph™ process
- Post end of quarter - Acute Myeloid Leukemia (AML) patient achieves Complete Response in CHM CORE-NK Phase 1b combination trial
- Partnership with Cell Therapies Pty Ltd to explore manufacturing Chimeric's CAR T-cell therapies in Australia
- Post end of quarter – Commitments received for $5m capital raising

FIRST PATIENT DOSED IN CHM CDH17 PHASE 1/2 CLINICAL TRIAL

In August, the first patient was dosed in the Company's Phase 1/2 clinical trial for CHM CDH17 CAR-T cell therapy at the Sarah Cannon Research Institute in Nashville, Tennessee. The trial is recruiting patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours at multiple U.S. cancer centres.

This followed earlier announcements of the first participant enrolment and the completion of Good Manufacturing Practice (GMP) manufacturing, enabling the treatment to proceed. The participant's cells were collected, underwent GMP manufacturing and Quality Assurance testing, and were then returned to the clinical site for infusion.

The Phase 1/2 trial (NCT06055439) is a two-stage study aimed at establishing a recommended Phase 2 dose of CHM CDH17 while evaluating its safety and objective response rate. The trial will initially enrol patients to select dose, followed by Phase 2 expansion into specific cancer cohorts.

Subsequently, the University of Pennsylvania (Penn) also opened enrolment for the trial, with additional sites expected to open by the end of 2024.

In September, Chimeric announced a collaboration with Achieve Clinics to expand patient access to CHM CDH17 through the use of Achieve's PRO-Aph™ process. This proactive apheresis method allows for the collection and cryopreservation of patient cells early in the cancer treatment process, improving patient outcomes by ensuring healthier cells are available for future CAR-T therapy. This collaboration is expected to enhance the efficiency of cell collection and expand access to patients while potentially improving accrual rates and development timelines.

CHM CDH17 is a third-generation CAR-T cell therapy that targets CDH17, a protein linked to poor prognosis and metastasis in gastrointestinal cancers. Preclinical studies from the University of Pennsylvania demonstrated that CHM CDH17 could eradicate tumours in several cancer models without causing toxicity to normal tissues. The CDH17 antigen is unique because it is fully exposed around solid tumour cells, like those found in colorectal cancer, making it a target for CAR-T cells to attack.

The CHM CDH17 CAR-T is also unique because it's a third-generation CAR, which means it has more components that can help it bind more effectively to the cancer cells. Previous CAR-T therapies tested on solid tumours have been second-generation, which haven't worked as well as those for blood cancers.

The CHM CDH17 CAR has been improved with six linkers, and it includes a special part that boosts its activity. Tests in animal models showed that these CAR-T cells can reach the tumour site and help reduce the tumours.

Additionally, the CHM CDH17 CAR enhances a specific immune response (IL-23), which helps turn "cold tumours" (those that don't attract the immune system to respond) into "hot tumours," making it easier for the immune system to recognize and destroy the cancer cells.

AML PATIENT ACHIEVES COMPLETE RESPONSE IN CHM CORE-NK COMBINATION PHASE 1B TRIAL

Subsequent to the end of the reporting period, Chimeric was pleased to provide an update on the CHM CORE-NK + Vactosertib Phase 1b clinical trial, after a Complete Response from an Acute Myelogenous Leukemia (AML) patient participating in the trial.

The ongoing Phase 1b study is building upon the clinical activity seen in the initial CHM CORE-NK Phase 1a clinical trial by adding Vactosertib, an oral TGF-β receptor inhibitor that was designed to disrupt the inhibitory TGF-β signaling pathway. The trial is the first ever to assess NK cells in

combination with Vactosertib in patients with advanced colorectal and blood cancers. This is the first and currently only patient treated in the blood cancer arm of the Phase 1b trial.

The new result is in addition to the previous result from the Phase 1a clinical trial announced on 16 May 2024, where a different patient in that trial also achieved a complete response that has now been sustained for 48 months (15 months complete response at the time of the initial CORE-NK study publication).

CHIMERIC PARTNERING WITH CELL THERAPIES AUSTRALIA

Chimeric Therapeutics announced a partnership with Cell Therapies Pty Ltd to explore manufacturing Chimeric's CAR T-cell therapies in Australia. Cell Therapies, based in Melbourne's Parkville Precinct, operates Australia's only facility capable of producing CAR T-cells on a commercial scale.

This collaboration aims to provide Australian patients with access to Chimeric's innovative clinical trials, focusing on cancer treatment through CAR T and NK cell therapies.

Chimeric currently has four clinical trials underway in the US and is exploring the addition of Australian sites.

CORPORATE

The Company released an investor update presentation in July. Click here to view a copy of the slides.

FINANCIAL

An Appendix 4C Quarterly Cash Flow report is attached to this announcement.

As detailed in the attached ASX Appendix 4C the Company had $3.10 million in cash and cash equivalents as at 30 September 2024, increasing from $3.05 million at the end of the prior quarter.

The Net Cash used in operating Activities during the quarter was $2.49 million with Staff costs and direct Research and Development expenditure accounting for over 93% as detailed further in the Appendix 4C.

The Net Financing inflows for the quarter was $2.56 million which consists of the R&D Advance entered into by the company in August and $1 million advanced by Paul Hopper as part of the October Placement. Paul's investment is subject to shareholder approval.

In accordance with Listing Rule 4.7C, payments made to related parties and their associates included in items 6.1 of the Appendix 4C include payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates, excluding reimbursement of out-of-pocket expenses. The Board has focused on prudent management of cash and as a result of careful cost cutting strategy projected total expenditure will be reduced.

COMMITMENTS RECEIVED FOR $5M PLACEMENT

In another event subsequent to the end of the reporting period, Chimeric advised it received commitments for a capital raising of $5 million (before costs) by way of a two-tranche placement to sophisticated and professional investors at an issue price of $0.008 (0.8 cents) per new fully paid ordinary share.

The capital raising was supported by a range of institutional, professional and sophisticated investors, with the new funds to be used primarily to advance the CHM CDH17 CAR-T program through the recently commenced Phase 1/2 clinical trial.

The issue of tranche two placement shares and any placement shares to be issued to Directors is subject to shareholder approval. The placement will see 625 million new fully paid placement shares issued at $0.008 per share together with 1 unlisted option (with an exercise price of $0.008, expiring 12 months from the grant date) for every 1 placement share issued, also subject to CHM shareholder approval.

Chimeric's Executive Chairman, Mr Paul Hopper, has committed to subscribe for 125 million shares (representing $1 million of the $5 million Placement) in the capital raising, to be issued to him or his nominee, subject to shareholder approval.

CHIMERIC RECEIVES $1.5M ADVANCE ON FY24 R&D TAX INCENTIVE

Chimeric received $1,562,000 from Endpoints Capital under a funding facility secured against the Company's anticipated FY24 Research and Development Tax Incentive (RDTI).

The funds will support the clinical trial pipeline and otherwise for general working capital of the Company.

The funding agreement with Endpoints Capital provides Chimeric with early access to a portion of the Company's anticipated FY24 RDTI. The facility is secured against the anticipated FY24 RDTI to be received from the Australian Taxation Office, with interest charged at a commercial rate.

CONTACT

Investors
Dr Rebecca McQualter
Chief Operating Officer
Chimeric Therapeutics
T: + 61 498 966 180
E: RMcQualter@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media
Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Chimeric Therapeutics Limited	
ABN	**Quarter ended ("current quarter")**
68 638 835 828	30 September 2024

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers (inclusive of GST)	-	-
1.2	Payments for (inclusive of GST)		
	(a) research and development	(846)	(846)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs*	(1,274)	(1,274)
	(f) administration and corporate costs	(424)	(424)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	11	11
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	
1.8	Other (provide details if material)	40	40
1.9	**Net cash from / (used in) operating activities**	**(2,493)**	**(2,493)**

*Staff costs includes staff, directors, scientific advisors and employment related costs.

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	1,000	1,000
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	1,562	1,562
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other – payments of licence fee liabilities	-	-
3.10	**Net cash from / (used in) financing activities**	**2,562**	**2,562**

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	3,053	3,053
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,493)	(2,493)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	2,562	2,562
4.5	Effect of movement in exchange rates on cash held	(21)	(21)
4.6	**Cash and cash equivalents at end of period**	**3,101**	**3,101**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	3,101	3,053
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**3,101**	**3,053**

6.	**Payments to related parties of the entity and their associates**	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	-
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Item 6.1 – Include payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates, excluding reimbursements of out-of-pocket expenses.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(2,493)
8.2	Cash and cash equivalents at quarter end (item 4.6)	3,101
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	**3,101**
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	1.24

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

- The Company anticipates a similar level of expenditure in the upcoming quarters.
- The Board and management are still focused on prudent management of cash and where possible will decrease the total expenditure.
- On 21 October 2024, the Company announced they had raised $5 million on the issue of 625 million share at $0.008 per share.
- In addition to the shares, investors will receive a free-attaching options that can be exercised at $0.008 and expires 12 months from grant date. If exercised, the options will raise the Company a further $5 million.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

- On 21 October 2024, the Company announced they had raised $5 million on the issue of 625 million share at $0.008 per share.
- In addition to the shares, investors will receive a free-attaching options that can be exercised at $0.008 and expires 12 months from grant date. If exercised, the options will raise the Company a further $5 million.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Yes the Board expects to be able to continue its operations and to meet its business objectives based on the responses detailed in 8.6.1 and 8.6.2.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 30 October 2024

Authorised by: The Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

Phone +61 3 98245254
Email info@chimerictherapeutics.com

Chimeric Therapeutics Limited

ACN 638 835 828

ASX: CHM

CHIMERIC THERAPEUTICS